Cormorant Pharmaceuticals Acquired by BMS for $520M

News   Jul 11, 2016

 
Cormorant Pharmaceuticals Acquired by BMS for $520M
 
 
 

RELATED ARTICLES

Working Together Helps Phage Overcome CRISPR

News

Surprising results show that phage join forces to overcome bacteria’s CRISPR -based immune defenses. Improved understanding of the interactions between phage and their bacterial hosts could help advance phage-based therapies and stimulate viral research.

READ MORE

Study in Mouse Model of Autism Finds Mother's Microbiome Determines Risk

News

The microbiome is the collection of microorganisms, such as bacteria, that naturally live inside us. New research in a mouse model suggests the microbiome determines autism risk.

READ MORE

A Carcinogen at the Gym

News

Gyms are places people go to get healthier. But nearly half the gyms in the U.S. contain a potentially addictive carcinogen - tanning beds, report UConn researchers.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma Cancer Research Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE
 

We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy